Abiopharma

🔍 Sanofi (Executive)

Company: Attovia Therapeutics, Inc. (ATTO)

Report Date: 2026-08-06

Detailed Transactions and Holdings:

• Acquired 782,855 shares of Common Stock (Direct)
  Date: 2026-08-06 | Code: C | equity_swap_involved: false | shares_owned_after: 782,855.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 300,000 shares of Common Stock at $17.0 per share (Direct)
  Date: 2026-08-06 | Code: P | equity_swap_involved: false | shares_owned_after: 1,082,855.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Sold 782,855 shares of Series C Preferred Stock (Derivative)
  Date: 2026-08-06 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F1, F3, F3

Footnotes:

• F1: The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026.
• F2: Represents a purchase in the Issuer's IPO.
• F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
• REMARKS: Immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock.